Efficacy and Safety of Evolocumab in Improving Low-Density Lipoprotein Cholesterol (LDL-C) Levels in a Japanese Population　- Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Hypercholesterolemia is a major risk factor for cardiovascular disorders. Evolocumab is efficacious and safe for the management of low-density lipoprotein cholesterol (LDL-C); however, evidence supporting the utility of evolocumab in Japanese patients is lacking. To fill this evidence gap, we conducted this systematic review and meta-analysis.

Methods and results

PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to October 2023 were searched for relevant publications. The primary outcomes were LDL-C levels and coronary artery plaque regression or stabilization. The secondary outcome was the incidence of adverse events. Nine studies were included: 6 randomized control trials (RCTs) and 3 cohort studies. The meta-analysis showed that evolocumab

SUBMITTER: Sheng F 

PROVIDER: S-EPMC12510974 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature